Power Law company profile

Bio-Thera Solutions

Biotech & Life Sciences · Guangzhou, China · Founded 2003 · IPO 2020 Unicorn

Produces innovative monoclonal antibodies, adalimumab biosimilars, innovative drugs, and other related products

Valuation

$1.23B

Market cap · May/2026

Revenue

$102M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Bio-Thera Solutions has talent and traffic

Workforce by country

3 countries with
team presence

🇨🇳 China87%

🇺🇸 United States8.7%

🇰🇷 South Korea4.3%

3 countries shown

Patent intelligence

$21M patent portfolio · 127 active families

Estimated portfolio value

$21M

1.7% of market cap · 15.4× smaller than top peer Genmab ($328M)

127 active patent families

Where Bio-Thera Solutions innovates Antiendomysial antibodiesMolecular biologyAnti antibodyPharmaceutical drugAntigen Binding Fragment

Where Bio-Thera Solutions concentrates vs peers

Each axis is a top-10 topic across Bio-Thera Solutions and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Bio-Thera Solutions

An AI-synthesized read of the highest-engagement posts about Bio-Thera Solutions on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bio-Thera Solutions on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles